Mark Stejbach
Fortune : 975 674 $ au 31/05/2026
Fortune : 975 674 $ au 31/05/2026
Mr. Mark P.
Stejbach is an Independent Non-Executive Director at Indivior Pharmaceuticals, Inc. and an Independent Non-Executive Director at Indivior Ltd. He is on the Board of Directors at Indivior Pharmaceuticals, Inc., Indivior Ltd. and Nirsum Laboratories, Inc. Mr. Stejbach was previously employed as an Independent Non-Executive Director by Flexion Therapeutics, Inc., a Chief Commercial Officer & Senior Vice President by Alkermes Plc, a Chief Commercial Officer by Tengion, Inc., a Principal by Biogen Idec MA, Inc., and a Vice President-Managed Care Marketing by Merck & Co., Inc. He also served on the board at Commonwealth National Fund, Inc. He received his undergraduate degree from Virginia Polytechnic Institute & State University and an MBA from The Wharton School of the University of Pennsylvania.
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
0,02% | 13/05/2026 | 27 087 ( 0,02% ) | 975 674 $ | 31/05/2026 |
| Sociétés | Poste | Début |
|---|---|---|
Indivior Ltd.
Indivior Ltd. Pharmaceuticals: MajorHealth Technology Develops and commercializes pharmaceutical drugs | Directeur/Membre du Conseil | 24/03/2021 |
Nirsum Laboratories, Inc.
Nirsum Laboratories, Inc. Pharmaceuticals: MajorHealth Technology Develops new medications for opioid use disorder | Directeur/Membre du Conseil | - |
| Sociétés | Poste | Fin |
|---|---|---|
| FLEXION THERAPEUTICS, INC. | Directeur/Membre du Conseil | 19/11/2021 |
| ALKERMES PLC | Corporate Officer/Principal | 01/10/2018 |
| TENGION, INC. | Public Communications Contact | 01/01/2012 |
Commonwealth National Fund, Inc.
Commonwealth National Fund, Inc. Financial ConglomeratesFinance Functions as investment fund | Directeur/Membre du Conseil | 01/01/2011 |
| MERCK & CO., INC. | Corporate Officer/Principal | 01/07/2008 |
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
| Entreprise privées | 10 |
|---|---|
Biogen MA, Inc.
Biogen MA, Inc. BiotechnologyHealth Technology Develops and manufactures drugs related to immunology, neurobiology and oncology | Health Technology |
Merck & Co., Inc.
Merck & Co., Inc. Pharmaceuticals: MajorHealth Technology Manufactures human and animal health pharmaceutical products & vaccines | Health Technology |
Tengion, Inc.
Tengion, Inc. BiotechnologyHealth Technology Develops new human organs and tissues | Health Technology |
Flexion Therapeutics, Inc.
Flexion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that discovers, develops and commercializes therapies for the treatment of patients with musculoskeletal conditions | Health Technology |
Indivior Ltd.
Indivior Ltd. Pharmaceuticals: MajorHealth Technology Develops and commercializes pharmaceutical drugs | Health Technology |
Virginia Polytechnic Institute & State University
Virginia Polytechnic Institute & State University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Alkermes Plc
Alkermes Plc Pharmaceuticals: MajorHealth Technology Manufactures and commercializes pharmaceutical products to treat neurodegenerative disorders and cancer | Health Technology |
The Wharton School of the University of Pennsylvania
The Wharton School of the University of Pennsylvania Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Commonwealth National Fund, Inc.
Commonwealth National Fund, Inc. Financial ConglomeratesFinance Functions as investment fund | Finance |
Nirsum Laboratories, Inc.
Nirsum Laboratories, Inc. Pharmaceuticals: MajorHealth Technology Develops new medications for opioid use disorder | Health Technology |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national